Is Elevance Health (ELV) a risky stock?
As of July 21, 2026, Clavix grades Elevance Health (ELV) C for risk, a composite score of 56 out of 100 on an A+ to F scale, which puts ELV in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind ELV's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ELV scores on each, as of July 21, 2026.
What's moving ELV's risk right now
Company-specific signals Clavix flags behind ELV's current grade, drawn from recent news and filings as of July 21, 2026.
Investors may face downside risk if Medicaid-related issues continue to drag on Elevance's earnings, potentially undermining the bullish narrative currently reflected in the stock…
Despite an earnings beat and raised guidance, Medicaid headwinds are creating enough concern among investors to overshadow the positive results and pressure the stock lower.
Price action is choppy but within normal bounds, offering no clear directional signal.
What a C grade means
On the Clavix A+ to F scale, ELV's composite of 56 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ELV or any security. Grades are risk indicators, not predictions of return. Data may be delayed.